抗糖尿病藥物市場－全球產業規模、佔有率、趨勢、機會、預測：按藥物類別、類型、給藥途徑、分銷管道、地區和競爭格局分類，2021-2031年

全球抗糖尿病藥物市場預計將從 2025 年的 909.9 億美元大幅成長至 2031 年的 1,671.8 億美元，複合年成長率為 10.67%。

從胰島素和磺醯尿素類藥物到GLP-1受體促效劑等新型療法，這些藥物製劑對於調節糖尿病患者的血糖值至關重要。這個市場的持續擴張主要受結構性因素驅動，例如全球肥胖率上升、人口老化導致代謝紊亂風險增加，以及都市化進程加快加劇了久坐的生活方式。這些結構性因素確保了對長期血糖管理解決方案的持續需求，使其不受處方習慣或品牌策略暫時性變化的影響。

儘管需求強勁，但先進療法的高成本構成了市場准入的重大障礙，導致中低收入地區患者獲得治療的機會不均等。嚴格的報銷政策和經濟差距往往限制了高階生物製藥的普及，並限制了其在新興經濟體中的獲利潛力。國際糖尿病聯盟的數據凸顯了提供價格合理且易於取得的治療方法的迫切性。聯盟報告稱，到2024年，全球將有約5.89億成年人患有糖尿病，凸顯了克服這些障礙的關鍵意義。

市場促進因素

對具有體重管理適應症的GLP-1受體促效劑的需求激增，正推動全球抗糖尿病藥物市場轉型，治療重點從單純的血糖控制轉向全面的代謝健康管理。這類藥物因其在治療第二型糖尿病之外，還能有效治療肥胖症，從而吸引了前所未有的關注，有效地將目標患者群體擴展到了傳統的胰島素依賴型患者之外。這一趨勢的商業性影響在關鍵製劑的爆炸性收入成長中得到了清晰體現。例如，禮來公司在2025年10月發布的2025年第三季財報中指出，其Munjaro的全球營收成長了109%，達到65.2億美元，凸顯了這些先進的腸促胰素療法的快速市場滲透和財務主導地位。

同時，全球第2型糖尿病盛行率的持續上升繼續推動著市場規模的永續發展，對口服生物製劑和胰島素療法的持續供應提出了更高的要求。隨著全球都市化的加速和久坐生活方式的日益普遍，大量確診患者需要可擴展的醫療干預措施和慢性病管理方案。根據國際糖尿病聯盟（IDF）發布的2025年版《IDF糖尿病地圖集》，目前全球約有11.1%的成年人患有糖尿病，因此迫切需要可及的治療方法。不斷擴大的患者群體與工業產出的成長直接相關，諾和諾德公司於2025年2月發布的2024年度報告也印證了這一需求的規模，該報告顯示，諾和諾德為超過4520萬名患有嚴重慢性疾病的患者提供服務。

市場挑戰

先進藥物製劑的高成本以及由此導致的低收入和中等收入地區患者難以公平獲得這些藥物，是全球抗糖尿病藥物市場成長的主要障礙。儘管臨床上對有效血糖控制的需求仍然強勁，但開發中國家的經濟差距阻礙了GLP-1受體促效劑等昂貴生物製藥的普及應用。在這些對價格高度敏感的市場中，醫療系統往往採用嚴格的報銷政策，優先考慮價格較低的學名藥，而非創新療法。這種對價格低廉的替代藥物的依賴嚴重限制了製藥企業的產生收入，因為他們無法充分利用經濟拮据地區不斷成長的患者群體。

這種結構性障礙使得很大一部分可確診者無法受益於高價值處方藥，造成了疾病負擔與經濟可近性之間的巨大差距。這種經濟差距的影響在疾病的地域分佈中得到了清楚的體現。根據國際糖尿病聯盟2024年的報告，超過80%的糖尿病成人患者將居住在中低收入國家。這項數據凸顯了一個嚴峻的挑戰：很大一部分市場集中在那些最無力負擔先進治療方案的地區。

市場趨勢

智慧互聯的給藥設備的整合正在從根本上重塑全球抗糖尿病藥物市場，將患者照護從人工、分散的干涉轉向自動化、數據驅動的生態系統。這一趨勢包括透過融合胰島素幫浦、智慧注射筆和持續血糖監測系統來建構封閉回路型演算法治療管理。這些技術透過最大限度地減少劑量計算中的人為誤差並實現即時遠端監測，顯著改善了血糖控制和治療依從性。先進自動化胰島素給藥系統的廣泛應用是這項技術變革商業性可行性的基礎。根據Medtronic於2025年11月發布的2026年第二季財報，全球糖尿病相關營收年增10.3%，這直接得益於這些平台在國際市場上的普及。

同時，具成本效益生物相似藥的市場進入正在改變競爭格局，為現有參考生物製藥（尤其是胰島素）提供價格更親民的替代方案。隨著傳統胰島素製劑專利的到期，Insulin Glargine和胰島素Aspart等生物相似藥的核准上市正在消除長期存在的價格壁壘，並促進其在價格敏感地區的市場滲透。這些低成本產品的湧入不僅威脅現有原廠藥生產商的定價權，也符合支付方降低慢性病相關支出的努力。專注於該領域的生產商所取得的財務成功凸顯了市場的接受度。根據百康有限公司（Biocon Limited）於2025年8月發布的“2026第一季業績報告”，在對價格合理的胰島素療法的持續需求推動下，生物類似藥業務的收入成長了18%，達到245.8億盧比。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球抗糖尿病藥物市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 藥物分類（胰島素、GLP-1受體促效劑、DPP-4抑制劑、SGLT2抑制劑、其他）
  • 按類型（類型 1、類型 2）
  • 給藥途徑（口服、皮下注射、靜脈注射）
  • 分銷通路（網路藥局、醫院藥局、零售藥局）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美抗糖尿病藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲抗糖尿病藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區抗糖尿病藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲抗糖尿病藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲抗糖尿病藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球抗糖尿病藥物市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• AstraZeneca Plc
• Bayer AG
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Pfizer, Inc.
• Johnson & Johnson
• Merck KGaA
• Novartis AG

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Antidiabetics Market is projected to expand significantly, growing from USD 90.99 Billion in 2025 to USD 167.18 Billion by 2031, reflecting a CAGR of 10.67%. These pharmaceutical formulations, which include therapies ranging from insulin and sulfonylureas to newer classes like GLP-1 receptor agonists, are essential for regulating blood glucose levels in patients with diabetes mellitus. This sustained market expansion is fundamentally driven by the rising global prevalence of obesity, an aging population susceptible to metabolic disorders, and increasing urbanization that fosters sedentary lifestyles. These structural factors ensure a continuous demand for long-term glucose management solutions, independent of temporary shifts in prescription habits or branding strategies.

Despite this strong demand, the market faces substantial hurdles due to the high cost of advanced therapies, which leads to inequitable access in low- and middle-income regions. Strict reimbursement policies and economic disparities often limit the widespread adoption of premium biologic treatments, restricting revenue potential in emerging economies. The urgency for affordable and accessible treatment options is highlighted by data from the 'International Diabetes Federation', which reported in '2024' that approximately 589 million adults worldwide were living with diabetes, underscoring the critical necessity of overcoming these barriers.

Market Driver

The surge in demand for GLP-1 Receptor Agonists with weight management indications acts as a transformative catalyst for the Global Antidiabetics Market, shifting the therapeutic focus from simple glycemic control to comprehensive metabolic health. This drug class has gained unprecedented traction due to its efficacy in treating obesity alongside Type 2 diabetes, effectively expanding the addressable patient population beyond traditional insulin-dependent cohorts. The commercial impact of this trend is evident in the explosive revenue growth of leading formulations; for instance, Eli Lilly and Company reported in their 'Q3 2025 Financial Results' in October 2025 that worldwide Mounjaro revenue increased 109% to $6.52 billion, highlighting the rapid market absorption and financial dominance of these advanced incretin-based treatments.

Concurrently, the escalating global prevalence of Type 2 Diabetes continues to serve as the foundational driver for sustained market volume, necessitating a constant supply of oral biologics and insulin therapies. As urbanization and sedentary behaviors become more entrenched globally, the sheer number of diagnosed individuals requires scalable healthcare interventions and chronic disease management solutions. According to the 'International Diabetes Federation', in the 'IDF Diabetes Atlas 11th Edition' published in 2025, approximately 11.1% of the global adult population is now living with diabetes, creating a critical need for accessible treatment regimens. This expanding patient base directly correlates with increased industrial output, a scale of demand underscored by Novo Nordisk in February 2025, reporting in its 'Annual Report 2024' that the company served more than 45.2 million people living with serious chronic diseases.

Market Challenge

The high cost of advanced pharmaceutical formulations and the subsequent lack of equitable access in low- and middle-income regions constitute a substantial barrier to the growth of the global antidiabetics market. While the clinical demand for effective glucose management is robust, economic disparities in developing nations prevent the widespread adoption of premium biologic therapies such as GLP-1 receptor agonists. Healthcare systems in these price-sensitive markets often enforce strict reimbursement policies that favor older, lower-cost generic medications over innovative treatments. This reliance on affordable alternatives significantly restricts revenue generation for manufacturers, as they are unable to fully monetize the expanding patient base in areas where financial resources are limited.

This structural impediment ensures that a vast segment of the diagnosable population remains underserved regarding high-value prescriptions, creating a disconnect between disease burden and financial capability. The impact of this economic gap is evident in the geographical distribution of the disease; according to the 'International Diabetes Federation' in '2024', it was reported that over 80 percent of adults living with diabetes resided in low- and middle-income countries. This statistic underscores the critical challenge, as the majority of the market's volume is concentrated in regions with the least capacity to afford sophisticated therapeutic solutions.

Market Trends

The Integration of Smart Connected Delivery Devices is fundamentally reshaping the Global Antidiabetics Market by transitioning patient care from manual, disparate interventions to automated, data-driven ecosystems. This trend involves the convergence of insulin pumps and smart pens with continuous glucose monitoring systems to create closed-loop, algorithmic therapy management. By minimizing human error in dosage calculation and enabling real-time remote monitoring, these technologies significantly enhance glycemic control and treatment adherence. The commercial viability of this technological shift is evidenced by the robust adoption of advanced automated insulin delivery systems; according to Medtronic in November 2025, in their 'Q2 Fiscal Year 2026 Financial Results', global diabetes revenue grew 10.3% year-over-year, directly attributed to the increasing uptake of these platforms in international markets.

Simultaneously, the Market Entry of Cost-Effective Biosimilars is altering the competitive landscape by introducing affordable alternatives to established reference biologics, particularly in the insulin segment. As patents for legacy insulin formulations expire, the approval and launch of biosimilar insulin glargine and aspart products are dismantling long-standing price barriers, thereby facilitating broader market penetration in price-sensitive regions. This influx of lower-cost options not only challenges the pricing power of incumbent originators but also aligns with payer efforts to reduce chronic disease expenditure. The financial success of manufacturers focusing on this segment confirms the market's receptivity; according to Biocon Limited in August 2025, in the 'Q1 FY26 Financial Results', revenue from the biosimilars segment increased 18% to Rs 2,458 crore, driven by sustained demand for their affordable insulin therapies.

Key Market Players

• AstraZeneca Plc
• Bayer AG
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Pfizer, Inc.
• Johnson & Johnson
• Merck KGaA
• Novartis AG

Report Scope

In this report, the Global Antidiabetics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antidiabetics Market, By Drug Class

• Insulin
• GLP-1 Receptor Agonists
• DPP- 4 Inhibitors
• SGLT2 Inhibitors
• Others

Antidiabetics Market, By Type

• Type 1
• Type 2

Antidiabetics Market, By Route of Administration

• Oral
• Subcutaneous
• Intravenous

Antidiabetics Market, By Distribution Channel

• Online pharmacies
• Hospital Pharmacies
• Retail pharmacies

Antidiabetics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antidiabetics Market.

Available Customizations:

Global Antidiabetics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antidiabetics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Insulin, GLP-1 Receptor Agonists, DPP- 4 Inhibitors, SGLT2 Inhibitors, Others)
  • 5.2.2. By Type (Type 1, Type 2)
  • 5.2.3. By Route of Administration (Oral, Subcutaneous, Intravenous)
  • 5.2.4. By Distribution Channel (Online pharmacies, Hospital Pharmacies, Retail pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Antidiabetics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Antidiabetics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Antidiabetics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Antidiabetics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Distribution Channel

7. Europe Antidiabetics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Type
  • 7.2.3. By Route of Administration
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Antidiabetics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Antidiabetics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Antidiabetics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Antidiabetics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Antidiabetics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Antidiabetics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Type
  • 8.2.3. By Route of Administration
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Antidiabetics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Antidiabetics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Antidiabetics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Antidiabetics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Antidiabetics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Antidiabetics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Antidiabetics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Antidiabetics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Antidiabetics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel

10. South America Antidiabetics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Type
  • 10.2.3. By Route of Administration
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Antidiabetics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Antidiabetics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Antidiabetics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Antidiabetics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AstraZeneca Plc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bayer AG
• 15.3. Takeda Pharmaceutical Company Limited
• 15.4. Eli Lilly and Company
• 15.5. Boehringer Ingelheim International GmbH
• 15.6. Bristol-Myers Squibb Company
• 15.7. Pfizer, Inc.
• 15.8. Johnson & Johnson
• 15.9. Merck KGaA
• 15.10. Novartis AG

16. Strategic Recommendations

17. About Us & Disclaimer